Analysis of the baseline performance of five UK lung cancer screening programmes

Lung cancer is the world ’s leading cause of cancer related death1. In the United Kingdom (UK) there are over 45,000 new cases and 35,000 deaths each year2. The symptomatic presentation of lung cancer is characteristically associated with advanced disease when treatments are ineffective and survival is very poor. Screenin g high-risk smokers and former smokers with LDCT detects early stage disease, prior to the development of symptoms, and reduces lung cancer specific mortality. This has been definitively demonstrated in two large randomised controlled trials (RCT), the National Lung Screening Trial (NLST) and the NE LSON trial3,4.

Source: Lung Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Haval Balata, Mamta Ruparel, Emma O'Dowd, Martin Ledson, John K. Field, Stephen W. Duffy, Samantha L Quaife, Anna Sharman, Sam Janes, David Baldwin, Richard Booton, Philip A.J. Crosbie Source Type: research